Emerging Therapy in Hypertension

被引:10
作者
Stewart, Merrill H. [1 ]
Lavie, Carl J. [1 ]
Ventura, Hector O. [1 ]
机构
[1] Univ Queensland, John Ochsner Heart & Vasc Inst, Ochsner Clin Sch, Sch Med, 1514 Jefferson Highway, New Orleans, LA 70121 USA
关键词
Hypertension; Future hypertension therapy; Hypertension drugs; Pharmacological therapy; High blood pressure; Hypertension medication; CHRONIC HEART-FAILURE; RENIN-ANGIOTENSIN SYSTEM; CONVERTING ENZYME 2; II TYPE-2 RECEPTOR; ALDOSTERONE SYNTHASE INHIBITION; AMINOPEPTIDASE-A INHIBITORS; FINERENONE VS. EPLERENONE; BLOOD-PRESSURE REDUCTION; ADD-ON THERAPY; DOUBLE-BLIND;
D O I
10.1007/s11906-019-0923-1
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Purpose of the ReviewPharmacology remains the mainstay of treatment for hypertension across the globe. In what may seem like a well-trodden field, there are actually an exciting array of new pathways for the treatment of hypertension on the horizon. This review seeks to discuss the most recent research in ongoing areas of drug development in the field of hypertension.Recent FindingsNovel areas of research in the field of hypertension pharmacology include central nervous system regulators, peripheral noradrenergic inhibitors, gastrointestinal sodium modulators, and a counter-regulatory arm of the renin-angiotensin-aldosterone system.SummaryThis review discusses these pathways in a look into the current status of emerging pharmacological therapies for hypertension.
引用
收藏
页数:9
相关论文
共 83 条
  • [1] Etamicastat, a Novel Dopamine β-Hydroxylase Inhibitor: Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Hypertension
    Almeida, Luis
    Nunes, Teresa
    Costa, Raquel
    Rocha, Jose F.
    Vaz-da-Silva, Manuel
    Soares-da-Silva, Patricio
    [J]. CLINICAL THERAPEUTICS, 2013, 35 (12) : 1983 - 1996
  • [2] Aldosterone Synthase Inhibition With LCI699 A Proof-of-Concept Study in Patients With Primary Aldosteronism
    Amar, Laurence
    Azizi, Michel
    Menard, Joel
    Peyrard, Severine
    Watson, Catherine
    Plouin, Pierre-Francois
    [J]. HYPERTENSION, 2010, 56 (05) : 831 - +
  • [3] Ardelyx, 2018, 26 WEEK STUD EV EFF
  • [4] Arnold AC, 2018, BLOOD PRESSURE LOWER
  • [5] Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug
    Balavoine, Fabrice
    Azizi, Michel
    Bergerot, Damien
    De Mota, Nadia
    Patouret, Remi
    Roques, Bernard P.
    Llorens-Cortes, Catherine
    [J]. CLINICAL PHARMACOKINETICS, 2014, 53 (04) : 385 - 395
  • [6] Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure
    Basu, Ratnadeep
    Poglitsch, Marko
    Yogasundaram, Haran
    Thomas, Jissy
    Rowe, Brian H.
    Oudit, Gavin Y.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (07) : 805 - 819
  • [7] Biaggioni I, 2018, CARDIOVASCULAR EFFEC
  • [8] Bial-Portela C S, 2018, SAFETY TOLERABILITY
  • [9] BOLTE E, 1958, Can Med Assoc J, V79, P881
  • [10] Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial
    Calhoun, David A.
    White, William B.
    Krum, Henry
    Guo, Weinong
    Bermann, Georgina
    Trapani, Angelo
    Lefkowitz, Martin P.
    Menard, Joel
    [J]. CIRCULATION, 2011, 124 (18) : 1945 - U124